Alfa Laval launches the first premium separator system for single-use biopharma processing
The CultureOne separator system uses product-contact parts that are replaceable and made from recyclable material.
Alfa Laval has launched a unique separator system, Alfa Laval CultureOne, for single-use processing in the biopharmaceutical industry.
All product-contact parts in the separator system can be replaced after each batch, which limits the need for onsite cleaning and sterilization, and eliminates the risk of cross-contamination, thereby increasing process hygiene and safety, as well as significantly improved turnaround time.
In addition, all product-contact parts are made from recyclable material, which chimes with the company's claims that its innovative technologies are "dedicated to purifying, refining, and reusing materials".
The Alfa Laval CultureOne separator system will be used in processes for harvesting fragile cell cultures which later can be used for injectable drugs for treating life-threatening illnesses such as cancer, rheumatoid arthritis and organ transplant rejection.
Nish Patel, President of the company's Food & Water Division said: "Now we can offer a premium separation technology for more effective production of smaller batches of targeted treatments. It is beneficial for our customers and society."
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.